RT Journal Article
T1 Should non-bacteraemic patients with a colonized catheter receive antimicrobial therapy?
A1 De Egea, V.
A1 Guembe, M.
A1 Rodríguez-Borlado, A.
A1 Pérez Granda, María Jesús
A1 Sánchez-Carrillo, C.
A1 Bouza Santiago, Emilio
AB ObjectivesThe impact of antimicrobial therapy on the outcomes of patients with colonized catheters and no bacteraemia has not been assessed. This study assessed whether targeted antibiotic therapy is related to a poor outcome in patients with positive cultures of blood drawn through a non-tunnelled central venous catheter (CVC) and without concomitant bacteraemia.MethodsThis was a retrospective study involving adult patients with positive blood cultures drawn through a CVC and negative peripheral vein blood cultures. Patients were classified into two groups: those with clinical improvement and those with a poor outcome. These two groups were compared. The outcome was considered poor in the presence of one or more of the following: death, bacteraemia or other infection due to the same microorganism, and evidence of catheter-related bloodstream infection.ResultsA total of 100 patients were included (31 with a poor outcome). The only independent predictors of a poor outcome were a McCabe and Jackson score of 1–2 and a median APACHE score of 5. No association was found between the use of targeted antimicrobial therapy and a poor outcome when its effect was adjusted for the rest of the variables.ConclusionsThis study showed that antimicrobial therapy was not associated with a poor outcome in non-bacteraemic patients with positive blood cultures drawn through a CVC.
PB Elsevier B.V.
SN 1201-9712
SN 1878-3511
YR 2017
FD 2017-09
LK https://hdl.handle.net/20.500.14352/120346
UL https://hdl.handle.net/20.500.14352/120346
LA eng
NO De Egea, Guembe, Rodríguez-Borlado, Pérez-Granda, Sánchez-Carrillo, Bouza. Should non-bacteraemic patients with a colonized catheter receive antimicrobial therapy? International Journal of Infectious Diseases. 2017;62:72-6.
NO M. Guembe cuenta con el apoyo del Programa Miguel Servet (ISCIII-MICINN, CP13/00268) del Fondo de Investigación en Salud (FIS) del Instituto de Salud Carlos III (ISCIII), en Madrid, España, financiado parcialmente por el Fondo Europeo de Desarrollo Regional (FEDER) bajo el lema “Una manera de hacer Europa”.
DS Docta Complutense
RD 17 dic 2025